In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sun Pharmaceutical Industries Ltd.

https://www.sunpharma.com/

Latest From Sun Pharmaceutical Industries Ltd.

Sun’s Specialty Gambit Paying Off, Tildrakizumab Nears Sales Milestone

Tildrakizumab, including Ilumetri end market numbers, nears $500m sales mark, with the contribution of Sun's wider specialty business nearly doubling since fiscal 2018. The anti-IL-23p19 monoclonal antibody has seen global sales spurt 81% in fiscal 2022, while acne therapy Winlevi has been well received by dermatologists in the US.

Strategy Sales & Earnings

Pfizer Latest Foreign Firm To Axe India Field Force Jobs: Here’s The Big Picture Take

Pfizer effects hundreds of field force job cuts in India as it rewires its commercialization approach and creates new roles leveraging its ‘digital core’, but industry experts suggest there is a complex mix of other factors at play as well.

India Commercial

The Quality Lowdown: Wishing Wished-For FDA Re-Inspections Had Gone Better?

As the COVID-19 pandemic wore on, industry clamored for the US FDA to re-inspect troubled drug manufacturing plants remotely if need be to clear them for new approvals. Now FDA investigators are out in force and early returns from Sun, Aurobindo, Lupin and Sterling suggest these re-inspections will be as tough as ever.

Manufacturing Quality

Halol Plant Approvals Still On Hold As Sun Responds To Lengthy FDA Inspection Report

After years of pandemic-related delays, US FDA reinspects key Sun plant in Halol, India, hit with “official action indicated” inspection findings that tabled approvals just before COVID-19 impeded travel. However, new findings are generating further discussions.

Manufacturing Quality
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Aditya Acquisition Company ltd
    • Caraco Pharmaceutical Laboratories, Ltd.
    • DUSA Pharmaceuticals, Inc.
    • InSite Vision, Inc.
    • JSC Biosintez
    • Ocular Technologies
    • Pola Pharma Inc.
    • Ranbaxy Laboratories Limited
    • Ranbaxy Solus
    • Solus Care
    • Sun Ophthalmics
    • Sun Pharma Global FZE
UsernamePublicRestriction

Register